June 21, 2024
MARSHFIELD – Marshfield Clinic Health System recently became the first healthcare system in the world to use the novel imaging agent, CYTALUX, in combination with the Stryker 1788 imaging platform for ovarian cancer surgery since CYTALUX received U.S. Food and Drug Administration approval. The new technology, CYTALUX, aids in ovarian cancer cytoreduction, or surgery to remove the tumor and any nearby tissues the cancer spread to.
This technology marks a significant milestone in the Health System's commitment to advancing patient care.
“We're the world's pioneer in bringing this revolutionary advancement into standard practice for the benefit of our patients," said Dr. Rohit Sharma, Marshfield Clinic Health System surgical oncologist and surgeon in the CYTALUX operating team. “CYTALUX will elevate our standard of surgical cytoreduction for ovarian cancer."
CYTALUX is the only FDA approved fluorescent imaging technology to light up lung cancer during surgery — enhancing surgeons' ability to visualize cancer in real time. The technology provides significant benefits to the surgical team and oncology patients, including:
- Instant, real-time visualization of cancer during surgery, which enables more precise and targeted removal of cancerous tissues.
- Improved accuracy during surgical procedures, enabling the detection of more cancer for removal.
- Minimal impact on surrounding healthy tissues, ensuring the surgery is as focused and non-invasive as possible.
- The ability to be used in various surgical settings and is also indicated for use in lung cancer.
This milestone was achieved through collaboration among the Health System's surgery, anesthesia, nursing and nursing operating room teams, pharmacy, and revenue cycle leadership teams.
“We are excite d about the positive impact this technology will have on patient outcomes and on our reputation as leaders and innovators in the health care field," said Dr. Adedayo Onitilo, medical director, Cancer Care & Research and oncology service line medical director. “We now stand as a forerunner in cancer care in the nation."
